Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study

Background: Rifampicin was reported to inhibit amyloid-β oligomerization and tau hyperphosphorylation in mouse models and could serve as a promising available medicine for the prevention of Alzheimer disease (AD). To examine whether rifampicin has such preventive effects in humans, we retrospectivel...

Full description

Bibliographic Details
Main Authors: Tomomichi Iizuka, Kozo Morimoto, Yuka Sasaki, Masashi Kameyama, Atsuyuki Kurashima, Kazumasa Hayasaka, Hideo Ogata, Hajime Goto
Format: Article
Language:English
Published: Karger Publishers 2017-06-01
Series:Dementia and Geriatric Cognitive Disorders Extra
Subjects:
Online Access:http://www.karger.com/Article/FullText/477343
_version_ 1818418151030784000
author Tomomichi Iizuka
Kozo Morimoto
Yuka Sasaki
Masashi Kameyama
Atsuyuki Kurashima
Kazumasa Hayasaka
Hideo Ogata
Hajime Goto
author_facet Tomomichi Iizuka
Kozo Morimoto
Yuka Sasaki
Masashi Kameyama
Atsuyuki Kurashima
Kazumasa Hayasaka
Hideo Ogata
Hajime Goto
author_sort Tomomichi Iizuka
collection DOAJ
description Background: Rifampicin was reported to inhibit amyloid-β oligomerization and tau hyperphosphorylation in mouse models and could serve as a promising available medicine for the prevention of Alzheimer disease (AD). To examine whether rifampicin has such preventive effects in humans, we retrospectively reviewed 18F-FDG-PET findings of elderly patients with mycobacterium infection treated with rifampicin. Methods: Forty nondemented elderly patients treated with rifampicin for mycobacterium infections who showed AD-type hypometabolism were enrolled. The hypometabolic patterns were evaluated with stereotaxic statistical analysis and region of interest analysis. Results: Before treatment, AD-type hypometa bolism was observed in 12 patients. The FDG uptake in the posterior cingulate cortex (PCC) was improved or stabilized in 6 patients after 12-month therapy (450 mg/day), whereas another 6 patients with 6-month therapy showed a decreased FDG uptake in the PCC. In patients who underwent FDG-PET only after treatment, the metabolic decline in the PCC was significantly milder in patients with ≥12 months of rifampicin treatment than in those with 6 months of treatment. Multiple regression analysis revealed that the dose of rifampicin and treatment duration significantly influenced FDG uptake in the PCC. Conclusion: The preventive effect of rifampicin depended on the dose and the treatment duration, and the effect needs at least 450 mg daily for 1 year.
first_indexed 2024-12-14T12:18:07Z
format Article
id doaj.art-e76ca4e46eb4479d8ba6539a8e4bc61e
institution Directory Open Access Journal
issn 1664-5464
language English
last_indexed 2024-12-14T12:18:07Z
publishDate 2017-06-01
publisher Karger Publishers
record_format Article
series Dementia and Geriatric Cognitive Disorders Extra
spelling doaj.art-e76ca4e46eb4479d8ba6539a8e4bc61e2022-12-21T23:01:35ZengKarger PublishersDementia and Geriatric Cognitive Disorders Extra1664-54642017-06-017220421410.1159/000477343477343Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up StudyTomomichi IizukaKozo MorimotoYuka SasakiMasashi KameyamaAtsuyuki KurashimaKazumasa HayasakaHideo OgataHajime GotoBackground: Rifampicin was reported to inhibit amyloid-β oligomerization and tau hyperphosphorylation in mouse models and could serve as a promising available medicine for the prevention of Alzheimer disease (AD). To examine whether rifampicin has such preventive effects in humans, we retrospectively reviewed 18F-FDG-PET findings of elderly patients with mycobacterium infection treated with rifampicin. Methods: Forty nondemented elderly patients treated with rifampicin for mycobacterium infections who showed AD-type hypometabolism were enrolled. The hypometabolic patterns were evaluated with stereotaxic statistical analysis and region of interest analysis. Results: Before treatment, AD-type hypometa bolism was observed in 12 patients. The FDG uptake in the posterior cingulate cortex (PCC) was improved or stabilized in 6 patients after 12-month therapy (450 mg/day), whereas another 6 patients with 6-month therapy showed a decreased FDG uptake in the PCC. In patients who underwent FDG-PET only after treatment, the metabolic decline in the PCC was significantly milder in patients with ≥12 months of rifampicin treatment than in those with 6 months of treatment. Multiple regression analysis revealed that the dose of rifampicin and treatment duration significantly influenced FDG uptake in the PCC. Conclusion: The preventive effect of rifampicin depended on the dose and the treatment duration, and the effect needs at least 450 mg daily for 1 year.http://www.karger.com/Article/FullText/477343Preventive therapyAlzheimer diseaseFDG-PETRifampicinAmyloid-βOligomer
spellingShingle Tomomichi Iizuka
Kozo Morimoto
Yuka Sasaki
Masashi Kameyama
Atsuyuki Kurashima
Kazumasa Hayasaka
Hideo Ogata
Hajime Goto
Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study
Dementia and Geriatric Cognitive Disorders Extra
Preventive therapy
Alzheimer disease
FDG-PET
Rifampicin
Amyloid-β
Oligomer
title Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study
title_full Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study
title_fullStr Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study
title_full_unstemmed Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study
title_short Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study
title_sort preventive effect of rifampicin on alzheimer disease needs at least 450 mg daily for 1 year an fdg pet follow up study
topic Preventive therapy
Alzheimer disease
FDG-PET
Rifampicin
Amyloid-β
Oligomer
url http://www.karger.com/Article/FullText/477343
work_keys_str_mv AT tomomichiiizuka preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy
AT kozomorimoto preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy
AT yukasasaki preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy
AT masashikameyama preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy
AT atsuyukikurashima preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy
AT kazumasahayasaka preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy
AT hideoogata preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy
AT hajimegoto preventiveeffectofrifampicinonalzheimerdiseaseneedsatleast450mgdailyfor1yearanfdgpetfollowupstudy